<DOC>
	<DOC>NCT02073656</DOC>
	<brief_summary>This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 weeks in hepatitis C virus (HCV) treatment-naive and treatment-experienced (including treatment intolerant) participants with chronic genotype 1 or 4 HCV infection who are co-infected with HIV-1. Participants who experience confirmed post-treatment virologic failure (relapse) at or before Posttreatment Week 24 may be eligible to be enrolled in the Retreatment Substudy to receive LDV/SOF plus ribavirin (RBV) for 24 weeks.</brief_summary>
	<brief_title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>HCV RNA â‰¥ 10,000 IU/mL at screening HCV genotype 1 or 4 HIV1 infection Cirrhosis determination, a fibroscan or liver biopsy may be required Screening laboratory values within defined thresholds Use of protocol specified method(s) of contraception if female of childbearing potential or sexually active male Clinicallysignificant illness (other than HCV or HIV) or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol Current or prior history of clinical hepatic decompensation, hepatocellular carcinoma (HCC), or other malignancy (with the exception of certain resolved skin cancers) Hepatitis B virus (HBV) infection Pregnant or nursing female Chronic use of systemically administered immunosuppressive agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>genotype 1</keyword>
	<keyword>genotype 4</keyword>
	<keyword>HIV</keyword>
</DOC>